A new study shows that the experimental drug axitinib slows tumor growth and/or shrinks tumors in patients with advanced thyroid cancer. Axitinib blocks receptors of vascular endothelial growth factor (VEGF), which plays a role in tumor formation by promoting the growth of blood vessels. Axitinib is a pill that can be taken by mouth.